RecruitingNCT06557668
Clinical Outcomes of Treatment With Immunomodulator Plus Cancer Therapies for Patients With Colorectal Cancer
Clinical Outcomes of Treatment With Immunomodulator Plus Standard Anti-cancer Therapies for Patients With Colorectal Cancer: A Retrospective Study
Sponsor
Taichung Veterans General Hospital
Enrollment
250 participants
Start Date
Aug 20, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to evaluate the survival and treatment outcomes among colorectal cancer patients undergoing anti-cancer treatment, both with and without an immunomodulator.
Eligibility
Min Age: 20 Years
Inclusion Criteria3
- Aged 20 years and older.
- Patients who have been given a diagnosis of colorectal cancer.
- Patients had previously initiated anti-cancer therapies between January 1, 2020, and Apr 30, 2024.
Exclusion Criteria1
- None
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06557668
Related Trials
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT0546403035 locations
Camera Capsule Endoscopy in the Routine Diagnostic Pathway for Colorectal Diseases
NCT064755601 location
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
NCT0624477126 locations
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors
NCT060775911 location
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations